208 related articles for article (PubMed ID: 31478341)
1. Impact of intrafraction prostate motion on clinical target coverage in proton therapy: A simulation study of dosimetric differences in two delivery techniques.
Su Z; Slopsema R; Flampouri S; Li Z
J Appl Clin Med Phys; 2019 Oct; 20(10):67-73. PubMed ID: 31478341
[TBL] [Abstract][Full Text] [Related]
2. SU-E-J-214: Target Intrafraction Motion Dosimetric Impact on 5-Fraction Proton Prostate SBRT.
Su Z; Slopsema R; Flampouri S; Li Z
Med Phys; 2012 Jun; 39(6Part9):3702. PubMed ID: 28519044
[TBL] [Abstract][Full Text] [Related]
3. Impact of intrafraction and residual interfraction effect on prostate proton pencil beam scanning.
Tang S; Deville C; Tochner Z; Wang KK; McDonough J; Vapiwala N; Both S
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1186-94. PubMed ID: 25442043
[TBL] [Abstract][Full Text] [Related]
4. Effect of intrafraction prostate motion on proton pencil beam scanning delivery: a quantitative assessment.
Tang S; Deville C; McDonough J; Tochner Z; Wang KK; Vapiwala N; Both S
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):375-82. PubMed ID: 23958148
[TBL] [Abstract][Full Text] [Related]
5. The dosimetric error due to uncorrected tumor rotation during real-time adaptive prostate stereotactic body radiation therapy.
Sengupta C; Skouboe S; Ravkilde T; Poulsen PR; Nguyen DT; Greer PB; Moodie T; Hardcastle N; Hayden AJ; Turner S; Siva S; Tai KH; Martin J; Booth JT; O'Brien R; Keall PJ
Med Phys; 2023 Jan; 50(1):20-29. PubMed ID: 36354288
[TBL] [Abstract][Full Text] [Related]
6. Single-fraction prostate stereotactic body radiotherapy: Dose reconstruction with electromagnetic intrafraction motion tracking.
Jaccard M; Ehrbar S; Miralbell R; Hagen T; Koutsouvelis N; Poulsen P; Rouzaud M; Tanadini-Lang S; Tsoutsou P; Guckenberger M; Zilli T
Radiother Oncol; 2021 Mar; 156():145-152. PubMed ID: 33310011
[TBL] [Abstract][Full Text] [Related]
7. An effective method to reduce the interplay effects between respiratory motion and a uniform scanning proton beam irradiation for liver tumors: A case study.
Akino Y; Wu H; Oh RJ; Das IJ
J Appl Clin Med Phys; 2019 Jan; 20(1):220-228. PubMed ID: 30548791
[TBL] [Abstract][Full Text] [Related]
8. Simulated real time image guided intrafraction tracking-delivery for hypofractionated prostate IMRT.
Hossain S; Xia P; Chuang C; Verhey L; Gottschalk AR; Mu G; Ma L
Med Phys; 2008 Sep; 35(9):4041-8. PubMed ID: 18841856
[TBL] [Abstract][Full Text] [Related]
9. Dosimetric impact of soft-tissue based intrafraction motion from 3D cine-MR in prostate SBRT.
de Muinck Keizer DM; Kontaxis C; Kerkmeijer LGW; van der Voort van Zyp JRN; van den Berg CAT; Raaymakers BW; Lagendijk JJW; de Boer JCJ
Phys Med Biol; 2020 Jan; 65(2):025012. PubMed ID: 31842008
[TBL] [Abstract][Full Text] [Related]
10. DMLC tracking and gating can improve dose coverage for prostate VMAT.
Colvill E; Poulsen PR; Booth JT; O'Brien RT; Ng JA; Keall PJ
Med Phys; 2014 Sep; 41(9):091705. PubMed ID: 25186380
[TBL] [Abstract][Full Text] [Related]
11. Intrafraction prostate translations and rotations during hypofractionated robotic radiation surgery: dosimetric impact of correction strategies and margins.
van de Water S; Valli L; Aluwini S; Lanconelli N; Heijmen B; Hoogeman M
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1154-60. PubMed ID: 24661668
[TBL] [Abstract][Full Text] [Related]
12. Geometric and dosimetric comparison of four intrafraction motion adaptation strategies for stereotactic liver radiotherapy.
Nankali S; Worm ES; Hansen R; Weber B; Høyer M; Zirak A; Poulsen PR
Phys Med Biol; 2018 Jul; 63(14):145010. PubMed ID: 29923837
[TBL] [Abstract][Full Text] [Related]
13. Dosimetric impact of intrafraction rotations in stereotactic prostate radiotherapy: A subset analysis of the TROG 15.01 SPARK trial.
Wolf J; Nicholls J; Hunter P; Nguyen DT; Keall P; Martin J
Radiother Oncol; 2019 Jul; 136():143-147. PubMed ID: 31015116
[TBL] [Abstract][Full Text] [Related]
14. The dosimetric effect of intrafraction prostate motion on step-and-shoot intensity-modulated radiation therapy plans: magnitude, correlation with motion parameters, and comparison with helical tomotherapy plans.
Langen KM; Chauhan B; Siebers JV; Moore J; Kupelian PA
Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1220-5. PubMed ID: 22483699
[TBL] [Abstract][Full Text] [Related]
15. Prospective MRI-based imaging study to assess feasibility of proton therapy for post-prostatectomy radiation.
Swisher-McClure S; Yin L; Rosen M; Batra S; Berman AT; Both S; Vapiwala N
Acta Oncol; 2016 Jul; 55(7):828-33. PubMed ID: 27145164
[TBL] [Abstract][Full Text] [Related]
16. Determination of action thresholds for electromagnetic tracking system-guided hypofractionated prostate radiotherapy using volumetric modulated arc therapy.
Zhang P; Mah D; Happersett L; Cox B; Hunt M; Mageras G
Med Phys; 2011 Jul; 38(7):4001-8. PubMed ID: 21858997
[TBL] [Abstract][Full Text] [Related]
17. Isotoxic dose prescription level strategies for stereotactic liver radiotherapy: the price of dose uniformity.
Hansen AT; Poulsen PR; Høyer M; Worm ES
Acta Oncol; 2020 May; 59(5):558-564. PubMed ID: 31833432
[No Abstract] [Full Text] [Related]
18. Simulated multileaf collimator tracking for stereotactic liver radiotherapy guided by kilovoltage intrafraction monitoring: Dosimetric gain and target overdose trends.
Poulsen PR; Murtaza G; Worm ES; Ravkilde T; O'Brien R; Grau C; Høyer M; Keall P
Radiother Oncol; 2020 Mar; 144():93-100. PubMed ID: 31786423
[TBL] [Abstract][Full Text] [Related]
19. A dosimetric comparison of ultra-hypofractionated passively scattered proton radiotherapy and stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.
Kole TP; Nichols RC; Lei S; Wu B; Huh SN; Morris CG; Lee S; Tong M; Mendenhall NP; Dritschilo A; Collins SP
Acta Oncol; 2015 Jun; 54(6):825-31. PubMed ID: 25227898
[TBL] [Abstract][Full Text] [Related]
20. Degradation of target coverage due to inter-fraction motion during intensity-modulated proton therapy of prostate and elective targets.
Thörnqvist S; Muren LP; Bentzen L; Hysing LB; Høyer M; Grau C; Petersen JB
Acta Oncol; 2013 Apr; 52(3):521-7. PubMed ID: 23409771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
